Candidate biomarkers in psychiatric disorders: state of the field

作者：Anissa Abi‐Dargham, Scott J. Moeller, Farzana Ali, Christine DeLorenzo, Katharina Domschke, Guillermo Horga, Amandeep Jutla, Roman Kotov, Martin P. Paulus, José M. Rubio, Gerard Sanacora, Jeremy Veenstra‐VanderWeele, John H. Krystal · 发表于：World Psychiatry · 年份：2023 · DOI：10.1002/wps.21078 · 被引用次数：376 · 研究领域：Functional Brain Connectivity Studies、Tryptophan and brain disorders、Mental Health Research Topics

The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can aid in objectively diagnosing patients and providing individualized treatment recommendations. Here we review and critically evaluate the evidence for the most promising biomarkers in the psychiatric neuroscience literature for autism spectrum disorder, schizophrenia, anxiety disorders and post-traumatic stress disorder, major depression and bipolar disorder, and substance use disorders. Candidate biomarkers reviewed include various neuroimaging, genetic, molecular and peripheral assays, for the purposes of determining susceptibility or presence of illness, and predicting treatment response or safety. This review highlights a critical gap in the biomarker validation process. An enormous societal investment over the past 50 years has identified numerous candidate biomarkers. However, to date, the overwhelming majority of these measures have not been proven sufficiently reliable, valid and useful to be adopted clinically. It is time to consider whether strategic investments might break this impasse, focusing on a limited number of promising candidates to advance through a process of definitive testing for a specific indication. Some promising candidates for definitive testing include the N170 signal, an event-related brain potential measured using electroencephalography, for subgroup identification within autism spectrum disorder; striatal resting-state functional magnetic resonance ...